We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hologic Wins FDA Approval for Genius 3D Mammography Exam
Read MoreHide Full Article
A leading player in the field of women's health, Hologic, Inc. (HOLX - Free Report) continues to expand its Breast and Skeletal Health business through innovation and product development. As a major breakthrough, the company has declared the receipt of FDA approval for its Genius 3D Mammography exam for women with dense breasts.
According to Hologic, Genius 3D Mammography is the only FDA-approved mammogram test superior to 2D mammography for routine breast cancer screening.
Numerous clinical studies have proved that this new exam improves the detection of breast cancer across different age groups while reducing recalls from women with different breast density. Among women aged 40 to 74 years, 40–50% percent have dense breasts. Here, breast density is only identifiable on imaging modalities like mammogram which reflects the amount of fibrous or glandular tissues is breasts. Women with dense breasts are at higher risk of developing breast cancer.
Also, the company has announced the availability of data from a previously published multicenter clinical study (JAMA 2014). The study had demonstrated how breast tomosynthesis can be treated as the standard of care in women aged 40 and above. The study also showed that tomosynthesis in digital mammography has significantly increased the detection rates for invasive cancer in women aged 40 to 69. The recall rates for all age groups also declined.
The company clearly has considerable potential in the breast imaging market. According to Markets and Markets, the breast imaging market is expected to reach a worth of $4.14 billion at a CAGR of 8.5% from 2016 to 2021.
Recent Developments
The recent acquisition of Medicor, a distributor of breast and skeletal health products in Germany, Austria and Switzerland, provides Hologic a nice platform for international growth.
Last year, the company had received FDA approval for the Affirm prone breast biopsy system. This system gives radiologists access to different angles of breasts without moving the patient much.
Zacks Rank & Key Picks
Hologic currently carries a Zacks Rank #3 (Hold). A few better-ranked medical stocks are Align Technology, Inc. (ALGN - Free Report) , Inogen, Inc. (INGN - Free Report) and Accelerate Diagnostics, Inc. (AXDX - Free Report) . Notably, Align Technologyand Inogen sport a Zacks Rank #1 (Strong Buy), while Accelerate Diagnostics carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Align Technologyhas an expected long-term adjusted earnings growth of almost 24%. The stock added roughly 43.8% over the last three months.
Inogen has a long-term expected earnings growth rate of 17.5%. The stock has a solid one-year return of around 81.4%.
Accelerate Diagnostics has an expected long-term adjusted earnings growth of 30%. The stock added roughly 9.8% over the last three months.
3 Top Picks to Ride the Hottest Tech Trend Zacks just released a Special Report to guide you through a space that has already begun to transform our entire economy...
Last year, it was generating $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for those who make the right trades early. Download Report with 3 Top Tech Stocks >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Hologic Wins FDA Approval for Genius 3D Mammography Exam
A leading player in the field of women's health, Hologic, Inc. (HOLX - Free Report) continues to expand its Breast and Skeletal Health business through innovation and product development. As a major breakthrough, the company has declared the receipt of FDA approval for its Genius 3D Mammography exam for women with dense breasts.
According to Hologic, Genius 3D Mammography is the only FDA-approved mammogram test superior to 2D mammography for routine breast cancer screening.
Numerous clinical studies have proved that this new exam improves the detection of breast cancer across different age groups while reducing recalls from women with different breast density. Among women aged 40 to 74 years, 40–50% percent have dense breasts. Here, breast density is only identifiable on imaging modalities like mammogram which reflects the amount of fibrous or glandular tissues is breasts. Women with dense breasts are at higher risk of developing breast cancer.
Hologic, Inc. Price
Hologic, Inc. Price | Hologic, Inc. Quote
Also, the company has announced the availability of data from a previously published multicenter clinical study (JAMA 2014). The study had demonstrated how breast tomosynthesis can be treated as the standard of care in women aged 40 and above. The study also showed that tomosynthesis in digital mammography has significantly increased the detection rates for invasive cancer in women aged 40 to 69. The recall rates for all age groups also declined.
The company clearly has considerable potential in the breast imaging market. According to Markets and Markets, the breast imaging market is expected to reach a worth of $4.14 billion at a CAGR of 8.5% from 2016 to 2021.
Recent Developments
The recent acquisition of Medicor, a distributor of breast and skeletal health products in Germany, Austria and Switzerland, provides Hologic a nice platform for international growth.
Last year, the company had received FDA approval for the Affirm prone breast biopsy system. This system gives radiologists access to different angles of breasts without moving the patient much.
Zacks Rank & Key Picks
Hologic currently carries a Zacks Rank #3 (Hold). A few better-ranked medical stocks are Align Technology, Inc. (ALGN - Free Report) , Inogen, Inc. (INGN - Free Report) and Accelerate Diagnostics, Inc. (AXDX - Free Report) . Notably, Align Technologyand Inogen sport a Zacks Rank #1 (Strong Buy), while Accelerate Diagnostics carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Align Technologyhas an expected long-term adjusted earnings growth of almost 24%. The stock added roughly 43.8% over the last three months.
Inogen has a long-term expected earnings growth rate of 17.5%. The stock has a solid one-year return of around 81.4%.
Accelerate Diagnostics has an expected long-term adjusted earnings growth of 30%. The stock added roughly 9.8% over the last three months.
3 Top Picks to Ride the Hottest Tech Trend
Zacks just released a Special Report to guide you through a space that has already begun to transform our entire economy...
Last year, it was generating $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for those who make the right trades early. Download Report with 3 Top Tech Stocks >>